Cargando…

Rapid and sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in a patient with nephrotic syndrome secondary to systemic juvenile idiopathic arthritis-related amyloidosis

AA amyloidosis, or secondary amyloidosis, is a rare but serious complication of chronic inflammatory diseases. Chronic inflammatory arthritis is the commonest cause of AA amyloidosis and, when the latter appears, treatment can be frustrating. Deposition of fibrils, derived from circulating acute-pha...

Descripción completa

Detalles Bibliográficos
Autores principales:	De La Torre, Miguel, Arboleya, Luis, Pozo, Sergio, Pinto, Jesús, Velasco, Julio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2011
Materias:	II. Clinical Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421601/ https://www.ncbi.nlm.nih.gov/pubmed/25984151 http://dx.doi.org/10.1093/ndtplus/sfr004

Ejemplares similares

Juvenile idiopathic arthritis complicated by amyloidosis with secondary nephrotic syndrome – effective treatment with tocilizumab
por: Kwiatkowska, Małgorzata, et al.
Publicado: (2015)

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
por: Murakami, Miho, et al.
Publicado: (2012)

Tocilizumab-effects on growth impairment in systemic juvenile idiopathic arthritis
por: Miyamae, Takako, et al.
Publicado: (2011)

Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis
por: Herlin, Troels
Publicado: (2010)

Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
por: Horneff, G, et al.
Publicado: (2015)

Tocilizumab for juvenile idiopathic arthritis: a single-center case series
por: Yazılıtaş, Fatma, et al.
Publicado: (2020)

Tocilizumab-induced hypofibrinogenemia in patients with systemic-onset juvenile idiopathic arthritis
por: He, Tingyan, et al.
Publicado: (2023)

Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review
por: Iannone, Claudia, et al.
Publicado: (2023)

Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment
por: Reiff, Andreas
Publicado: (2012)

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
por: Horneff, Gerd, et al.
Publicado: (2017)

Safety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis
por: Alexeeva, E, et al.
Publicado: (2011)

The use of tocilizumab in a child with systemic onset juvenile idiopathic arthritis and ganglioneuroblastoma
por: Goran, Ristic, et al.
Publicado: (2011)

Efficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis
por: Nemiche, O, et al.
Publicado: (2011)

Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab
por: De Benedetti, Fabrizio, et al.
Publicado: (2014)

Effects of antirheumatic treatment with tocilizumab on longitudinal growth in children with juvenile idiopathic arthritis
por: Alexeeva, Ekaterina, et al.
Publicado: (2014)

Tocilizumab therapy in systemic juvenile idiopathic arthritis – lessons of real clinical practice
por: Kaleda, Maria I, et al.
Publicado: (2014)

Tocilizumab in the treatment of systemic-onset juvenile idiopathic arthritis – single-centre experience
por: Roszkiewicz, Justyna, et al.
Publicado: (2018)

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2021)

Sequential Tocilizumab and Tofacitinib Treatment for Systemic Juvenile Idiopathic Arthritis: a Case Report
por: Zhang, Ye, et al.
Publicado: (2022)

Correlations between serum interleukin 6, serum soluble interleukin 6 receptor, and disease activity in systemic juvenile idiopathic arthritis patients treated with or without tocilizumab
por: Vilaiyuk, Soamarat, et al.
Publicado: (2019)

Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review
por: Chantarogh, Songkiat, et al.
Publicado: (2017)

Secondary Osteoporosis in Patients with Juvenile Idiopathic Arthritis
por: Brabnikova Maresova, Kristyna
Publicado: (2011)

Tocilizumab (TCZ) may be an effective treatment for poly-juvenile idiopathic arthritis (pJIA) as for rheumatoid arthritis (RA)
por: Yamaguchi, Ken-ichi, et al.
Publicado: (2012)

PReS-FINAL-2110: Tocilizumab for patients with oligoarticular juvenile idiopathic arthritis refractory to conventional therapy
por: Sato, T, et al.
Publicado: (2013)

Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2019)

Cyclophosphamide therapy for secondary amyloidosis in a patient with juvenile idiopathic arthritis unresponsive to tumor necrosis factor α inhibitor therapy
por: Han, Sun Ae, et al.
Publicado: (2016)

2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)
por: Yokota, S, et al.
Publicado: (2008)

Cost–utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand
por: Kittiratchakool, Nitichen, et al.
Publicado: (2020)

Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
por: Shimizu, Masaki, et al.
Publicado: (2020)

Tocilizumab in Systemic Juvenile Idiopathic Arthritis: Response Differs by Disease Duration at Medication Initiation and by Phenotype of Disease
por: Yan, Xin, et al.
Publicado: (2021)

The Role of Interleukin-17 in Juvenile Idiopathic Arthritis: From Pathogenesis to Treatment
por: Paroli, Marino, et al.
Publicado: (2022)

PReS-FINAL-2166: Long-term safety and effectiveness of anti-interleukin-6 receptor monoclonal antibody, tocilizumab, in patients with systemic juvenile idiopathic arthritis in Japan
por: Yokota, S, et al.
Publicado: (2013)

Interleukin-4 and Interleukin-13 Gene Polymorphisms in Children With Idiopathic Nephrotic Syndrome
por: Al Rushood, Maysoun, et al.
Publicado: (2020)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data
por: De Benedetti, F, et al.
Publicado: (2011)

PReS-FINAL-2041: Macrophage activation syndrome in the children with systemic juvenile idiopathic arthritis during the course of tocilizumab
por: Alekseeva, E, et al.
Publicado: (2013)

Short-Term Outcomes and Predictors of Effectiveness of Tocilizumab in Systemic Juvenile Idiopathic Arthritis: A Prospective Cohort Study
por: Nada, Doaa W., et al.
Publicado: (2021)

Recovery fulminant hepatitis A in systemic juvenile idiopathic arthritis patient treated with tocilizumab: a case report
por: Kudsi, Maysoun, et al.
Publicado: (2023)

Juvenile idiopathic arthritis
por: Bhatt, Krupa H, et al.
Publicado: (2014)

Juvenile Idiopathic Arthritis
por: Barut, Kenan, et al.
Publicado: (2017)

Interleukin-6 overproduction correlates with disease activity and severity in juvenile idiopathic arthritis
por: Spirchez, Mihaela, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_7m3aificjhrk4dboh0u2egt2jg